Cancer/testis antigen 1 (94-102)

Cancer/testis antigen 1 (94-102) is a synthetic peptide fragment derived from the well-characterized cancer/testis antigen 1 protein, also known as NY-ESO-1. This nonapeptide represents amino acids 94 through 102 of the parent protein, a sequence that is highly immunogenic and selectively expressed in various tumor types but largely absent from normal adult tissues, except for the testis. The unique expression profile and immunological relevance of this epitope have made it a focal point in cancer immunology research, particularly in the study of antigen presentation, T cell recognition, and tumor vaccine development. Its well-defined sequence and biochemical properties provide a robust platform for investigating cellular immune responses and advancing peptide-based experimental approaches in oncology.

Antigen presentation studies: Researchers utilize the 94-102 peptide fragment to investigate the mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) molecules, particularly HLA-A2. By loading this defined epitope onto antigen-presenting cells, scientists can dissect the efficiency and specificity of peptide-MHC complex formation, facilitating detailed analysis of immune synapse formation and T cell activation. This approach enables the elucidation of key steps in the immune recognition of tumor-associated antigens and supports the rational design of immunotherapeutic strategies.

T cell epitope mapping: The defined sequence of this peptide serves as a critical tool for mapping cytotoxic T lymphocyte (CTL) epitopes within the NY-ESO-1 protein. By exposing peripheral blood mononuclear cells or established T cell lines to the 94-102 fragment, investigators can identify and characterize peptide-specific T cell populations, assess their functional avidity, and determine cross-reactivity with related antigens. This application is instrumental in advancing the understanding of tumor-specific immune responses and in evaluating candidate epitopes for immunological monitoring.

Immunogenicity assays: The peptide is widely employed in ex vivo and in vitro immunogenicity assays to measure the frequency and functionality of antigen-specific T cells in patient samples or experimental models. Its use in enzyme-linked immunospot (ELISpot), intracellular cytokine staining, or tetramer-based flow cytometry allows for accurate quantification of T cell responses following immunization, tumor progression, or experimental manipulation. These assays provide insights into the immunodominance and persistence of T cell responses directed against cancer/testis antigens.

Peptide-based vaccine research: The 94-102 fragment is a prototypical epitope in the development and preclinical evaluation of peptide-based cancer vaccines. Its ability to bind specific MHC alleles and elicit robust T cell responses makes it an ideal candidate for inclusion in vaccine formulations aimed at stimulating targeted anti-tumor immunity. Studies employing this peptide often focus on optimizing delivery systems, adjuvant selection, and combinatorial strategies to enhance immunogenicity and specificity in model systems.

Functional studies of immune modulation: Beyond direct T cell activation, the peptide is also instrumental in exploring mechanisms of immune regulation, tolerance, or escape within the tumor microenvironment. By employing the 94-102 sequence in co-culture assays or functional blockade experiments, researchers can interrogate the roles of regulatory T cells, checkpoint molecules, or suppressive cytokines in modulating antigen-specific responses. These studies contribute to a deeper understanding of immune evasion in cancer and inform the development of novel immunomodulatory interventions.

1. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

2. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors

3. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

4. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

5. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats